Tags : Oncology Portfolio

Amgen Acquires Stake in BeiGene to Expand its Oncology Portfolio

Shots: BeiGene to commercialize Amgen’s Xgeva (denosumab), Kyprolis (carfilzomib) and Blincyto (blinatumomab) in China (Ex- Hong Kong, Macao & Taiwan) for 5 or 7yrs. with equal profit & loss sharing and will retain rights for one product plus will receive royalties on sales in China for an additional 5 yrs. on the products not retained […]Read More

Mylan Launches Generic Faslodex Injection for the Expansion of its

Shots: Mylan launches Fulvestrant Injection (50 mg/mL)/single-dose prefilled syringe which is a generic version of AstraZeneca’s Faslodex Injection and has received FDA’s ANDA as monothx. for advanced BC in women with menopause and combination therapy for advance & m-BC The launch of Fulvestrant Injection expands Mylan’s oncology portfolio and available treatment options for women facing […]Read More